This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn the United States, drug shortages have become a persistent public health issue, negatively impacting patient care and outcomes. In the last decade, the...
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...
CRA is a proud sponsor of the event. Kaitlyn Austin presents the session titled “Securing Insight Alignment to Drive Future-Proofed Strategies and...
